ClinicalTrials.gg
RecruitingNCT04533152PDFUpdated Jan 15, 2026

Prognostic Determinants in Patients With Diabetic Foot Ulcer.

An observational study in Diabetic Foot Ulcer, sponsored by University Hospital, Bordeaux. Recruiting at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by University Hospital, Bordeaux · Observational

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Diabetic Foot with a site in France — 12 open to participants now, 12 under way, none of them phase 3. Diabetic Foot · France.

Planned enrollment
2nd of 20
1,000 · median 140
Started
2021
with 4 others
Observational
20 of 55
4 open now
Primary completion
2029-11
later than 11 of 11 live
Registered
42nd of 55
by date

Among the 55 studies in Diabetic Foot with a site in France, this one is the 2nd largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2021, is one of 20 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 42nd registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

12 of the 55 studies in Diabetic Foot with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Diabetic Foot with a site in France, or all of them as a file.
02

Study summary

The worse prognosis observed in patients with Diabetic Foot Ulcer (DFU) has not been fully understood. Poor prognosis may be related to other conditions (inflammation, infectious disease, cancers) further to cardiovascular disease.

The aim of the study is to conduct the first prospective, observational and multi-centre cohort of patients with DFU in France, in order to evaluate the 5-years mortality rate, its causes and relevant prognostic determinants.

Read the detailed description

Diabetic foot ulcer (DFU) is one of the major complications frequently observed in patients with diabetes. DFU is the leading cause of non-traumatic lower-limb amputation (LLA), and it is associated with cognitive decline, worsening quality of life and substantial economic impact on French healthcare system. DFU is also associated with excess risk of premature death with significant decrease in life expectancy despite major improvement in medical care during last decades. The hypothesis of the study is that this worse prognosis seen in DFU patients may not be fully explained by a high cardiovascular risk, but mainly linked to different causes, including inflammatory, infectious and malignant conditions.

In addition, to conduct the first prospective, observational and multi-centre cohort of patients with DFU in France to evaluate the 5-years mortality rate, its causes and relevant prognostic determinants, the investigators will also assess all changes in health-related quality of life (HRQoL), and the economic impact related to DFU (cost of illness study) for the French healthcare system, using SNDS claims databases. A 3-year inclusion period will start during 2020, and each participant will be followed for 5 years or until death.

03

Conditions studied

  • Diabetic Foot Ulcer

Keywords

  • Diabetes mellitus
  • Lower-limb amputation
  • Wound
  • Health-related quality of life
  • Cost-of-illness
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

PDF study is designed to be the first French multicentre, observational and prospective cohort of patients with DFU referred from the community into secondary and tertiary care foot clinics.

Twenty-three French centres agreed to participate in this study. Each centre will recruit during the 3-year inclusion period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults with diabetes and DFU, defined as a foot skin ulceration or open LLA wound, measuring at least 5 mm of diameter, located below the malleolus, and induced by diabetic complications. In the case of an amputation before inclusion, the amputation stump will be considered as the main wound and not the wound that led to the amputation.

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic lower-limb ischemia without open skin wound,
  • Foot infection without open skin wound,
  • Intercurrent disease prohibiting participation in an observational study,
  • Pregnancy or breastfeeding
  • Curatorship or guardianship
  • Prisoners -- Patient currently participating to more than one other clinical study (interventional or observational, 2 study maximum including PDF) or currently participating to another study interfering with standard care of diabetic foot
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. DFU risk score

    Construct a DFU risk score equation of all-death will be computed to determine individuals with the higher risk of worse outcomes.

    Time frame: 5 years after inclusion

Secondary outcomes

  1. Survival without active index DFU

    Time frame: At 3 and 12 months after inclusion day

  2. Survival without recurrent index DFU

    Time frame: At 12, 24, 36, 48, 60 months after inclusion day

  3. Survival without major adverse limb events (MALE)

    MALE is a composite of foot infection, non-traumatic lower-limb amputation (LLA), requirement of revascularization, whichever comes first. These components will be also considered individually.

    Time frame: 5 years after inclusion

  4. Survival without major macrovascular events (MACE)

    MACE is a composite of non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure, or cardiovascular death, whichever comes first.

    Time frame: 5 years after inclusion

  5. Survival without major microvascular events (MICE)

    MICE is a composite of new-onset persistent macroalbuminuria, sustained 40% declined eGFR from baseline, ESRD, severe diabetic retinopathy or macular oedema requiring laser photocoagulation or intravitreal therapies, or diabetes-related blindness in either eye, whichever comes first.

    Time frame: 5 years after inclusion

07

Study locations

23 of 26 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Nov 2029, 96 months after the start.

Of 65 non-industry observational studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 94. This study's planned 96 months is above that.

Counting every sponsor, half of 90 studies reached it within 29 months; a quarter within 15 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2020
First posted
Aug 31, 2020
StartActual
Nov 24, 2021
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04533152
Collaborators
Fondation Francophone pour la Recherche sur le Diabete
Responsible party
Sponsor
First posted
Aug 31, 2020
Start date
Nov 24, 2021
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Jan 15, 2026

Study contacts

Kamel MOHAMMEDI, Pr
Contact
kamel.mohammedi@chu-bordeaux.fr
5 57 65 60 78 ext. +33
Vincent RIGALLEAU, Pr
Contact
vincent.rigalleau@chu-bordeaux.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion